TRIMTECH Therapeutics, a biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, today announced the appointment of Alison Lawton as Chair of its Board of Directors. Alison brings substantial expertise in operations, drug development, and strategic leadership, together with extensive boardroom experience, to guide and support TRIMTECH’s accelerated portfolio advancement and its next stage of growth.
https://trimtechtherapeutics.com/wp-content/uploads/2025/02/TRIMTECHTx_Logo_RGB.svg00webmasterhttps://trimtechtherapeutics.com/wp-content/uploads/2025/02/TRIMTECHTx_Logo_RGB.svgwebmaster2025-12-02 09:00:162025-12-02 09:00:58TRIMTECH Therapeutics appoints Alison Lawton as Chair of the Board
TRIMTECH Therapeutics, a biotech company creating novel, small molecule therapeutics that selectively degrade protein aggregates, to combat neurodegenerative diseases, today announced the appointment of Dr Mike Hutton to its Scientific Advisory Board (SAB). Mike will provide expert guidance to support the development of the Company’s targeted protein degradation (TPD) TRIMTAC™ and TRIMGLUE™ pipeline, including for Alzheimer’s and Parkinson’s disease targets.
https://trimtechtherapeutics.com/wp-content/uploads/2025/02/TRIMTECHTx_Logo_RGB.svg00webmasterhttps://trimtechtherapeutics.com/wp-content/uploads/2025/02/TRIMTECHTx_Logo_RGB.svgwebmaster2025-11-11 09:03:512025-11-11 09:03:51TRIMTECH Therapeutics appoints Dr Mike Hutton to Scientific Advisory Board
Fierce 15 highlights pre-commercial biotech companies driving the next generation of therapies for patients worldwide Cambridge, UK, 22 September 2025: TRIMTECH Therapeutics, a biotech company creating novel, small molecule therapeutics that selectively degrade protein aggregates to combat neurodegenerative diseases, today announced that it has been named as one of Fierce Biotech’s 2025’s ‘Fierce 15’ for […]
https://trimtechtherapeutics.com/wp-content/uploads/2025/02/TRIMTECHTx_Logo_RGB.svg00webmasterhttps://trimtechtherapeutics.com/wp-content/uploads/2025/02/TRIMTECHTx_Logo_RGB.svgwebmaster2025-09-22 14:20:002025-09-22 14:20:00TRIMTECH Therapeutics named as one of Fierce Biotech’s ‘Fierce 15’ for 2025
TRIMTECH Therapeutics, a biotech company creating novel, small molecule therapeutics that selectively degrade protein aggregates, to combat neurodegenerative diseases, today announced the formation of its Scientific Advisory Board (SAB).
TRIMTECH Therapeutics, a biotech company harnessing targeted protein degradation (TPD) for the treatment of neurodegenerative diseases, today announced the closing of its $31 million (£25 million) seed funding round. The financing was led by Cambridge Innovation Capital (CIC) and SV Health Investors’ Dementia Discovery Fund (DDF), with M Ventures and Pfizer Ventures joining. Additional investors also include Eli Lilly and Company, MP Healthcare Venture Management (MPH), Cambridge Enterprise Ventures, and Start Codon.
https://trimtechtherapeutics.com/wp-content/uploads/2025/02/TRIMTECHTx_Logo_RGB.svg00webmasterhttps://trimtechtherapeutics.com/wp-content/uploads/2025/02/TRIMTECHTx_Logo_RGB.svgwebmaster2025-03-05 14:00:032025-05-21 09:22:44TRIMTECH Therapeutics raises $31M seed funding to advance targeted protein degradation pipeline for treatment of neurodegenerative diseases
TRIMTECH Therapeutics appoints Alison Lawton as Chair of the Board
TRIMTECH Therapeutics, a biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, today announced the appointment of Alison Lawton as Chair of its Board of Directors. Alison brings substantial expertise in operations, drug development, and strategic leadership, together with extensive boardroom experience, to guide and support TRIMTECH’s accelerated portfolio advancement and its next stage of growth.
TRIMTECH Therapeutics appoints Dr Mike Hutton to Scientific Advisory Board
TRIMTECH Therapeutics, a biotech company creating novel, small molecule therapeutics that selectively degrade protein aggregates, to combat neurodegenerative diseases, today announced the appointment of Dr Mike Hutton to its Scientific Advisory Board (SAB). Mike will provide expert guidance to support the development of the Company’s targeted protein degradation (TPD) TRIMTAC™ and TRIMGLUE™ pipeline, including for Alzheimer’s and Parkinson’s disease targets.
TRIMTECH Therapeutics named as one of Fierce Biotech’s ‘Fierce 15’ for 2025
Fierce 15 highlights pre-commercial biotech companies driving the next generation of therapies for patients worldwide Cambridge, UK, 22 September 2025: TRIMTECH Therapeutics, a biotech company creating novel, small molecule therapeutics that selectively degrade protein aggregates to combat neurodegenerative diseases, today announced that it has been named as one of Fierce Biotech’s 2025’s ‘Fierce 15’ for […]
TRIMTECH Therapeutics establishes Scientific Advisory Board
TRIMTECH Therapeutics, a biotech company creating novel, small molecule therapeutics that selectively degrade protein aggregates, to combat neurodegenerative diseases, today announced the formation of its Scientific Advisory Board (SAB).
TRIMTECH Therapeutics raises $31M seed funding to advance targeted protein degradation pipeline for treatment of neurodegenerative diseases
TRIMTECH Therapeutics, a biotech company harnessing targeted protein degradation (TPD) for the treatment of neurodegenerative diseases, today announced the closing of its $31 million (£25 million) seed funding round. The financing was led by Cambridge Innovation Capital (CIC) and SV Health Investors’ Dementia Discovery Fund (DDF), with M Ventures and Pfizer Ventures joining. Additional investors also include Eli Lilly and Company, MP Healthcare Venture Management (MPH), Cambridge Enterprise Ventures, and Start Codon.